Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Ivacaftor - Vertex Pharmaceuticals

Next Previous
X
Search
Drug Profile

Ivacaftor - Vertex Pharmaceuticals

Alternative Names: IVA; Kalydeco; Potentiator VX-770; VRT 813077; VX-770

Latest Information Update: 13 May 2024

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Cystic Fibrosis Foundation Therapeutics; Vertex Pharmaceuticals
  • Developer Vertex Pharmaceuticals
  • Class Amides; Aminophenols; Quinolones; Small molecules
  • Mechanism of Action Cystic fibrosis transmembrane conductance regulator stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Cystic fibrosis
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Cystic fibrosis
  • Phase II Chronic obstructive pulmonary disease

Most Recent Events

  • 26 Apr 2024 European Commission approves ivacaftor for Cystic fibrosis for infants down to 1 month of age with CFTR gene mutations
  • 23 Feb 2024 The CHMP of EMA adopts a positive opinion recommending expansion of usage of ivacaftor for treatment of Cystic fibrosis (In infants aged 1-4 months)
  • 02 Oct 2023 Vertex Pharmaceuticals completes a phase III trial for Cystic fibrosis (In neonates, In infants, In children) in USA, Australia, Canada, Germany, Ireland and United Kingdom (NCT03277196)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top